IgA nephropathy associated with Crohn's disease

Tamura, Hiroshi

doi:10.5662/wjm.v13.i3.67

Cited by 2 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 Furthermore, in a series review of 23 patients with both CD and IgAN, 17 had simultaneous development of both conditions. 2 There is inconsistency in the literature as to whether UC or CD is more commonly associated with IgAN. 2 , 4 , 5 The same 2021 study also showed a higher risk of IgAN progressing to end-stage renal disease in patients with IBD: 50% of patients with IBD compared with 25% of patients with primary IgAN progressed to end-stage renal disease (odds ratio [OR]: 2.6 [95% confidence interval [CI] 2.02–3.35]).…”

Section: Discussionmentioning

confidence: 99%

“… 2 There is inconsistency in the literature as to whether UC or CD is more commonly associated with IgAN. 2 , 4 , 5 The same 2021 study also showed a higher risk of IgAN progressing to end-stage renal disease in patients with IBD: 50% of patients with IBD compared with 25% of patients with primary IgAN progressed to end-stage renal disease (odds ratio [OR]: 2.6 [95% confidence interval [CI] 2.02–3.35]). 5 In addition, it is unclear whether IgAN disease activity is associated with IBD disease activity.…”

Section: Discussionmentioning

confidence: 99%

“…Renal disease is a rare EIM, with immunoglobulin A nephropathy (IgAN) and tubulointerstitial nephritis being the most common associated renal disorders. 2 , 3 We present a patient who was diagnosed with both IgAN and Crohn's disease (CD) within 1 month. Treatment with risankizumab, an interleukin (IL)-23 inhibitor, effectively treated both his CD and IgAN.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Crohn's Disease Associated With IgA Nephropathy Effectively Treated With the Interleukin-23 Inhibitor Risankizumab

Larson,

Munir,

Rao

et al. 2024

ACG Case Rep J

View full text Add to dashboard Cite

Extraintestinal manifestations (EIMs) are common in inflammatory bowel disease (IBD). Renal EIMs, including immunoglobulin A nephropathy (IgAN), are relatively rare. EIMs are important to consider when developing a treatment plan for IBD. Studies differ on whether IBD disease activity correlates with IgAN disease activity. Published guidance on effective therapies for IBD-associated IgAN is limited. This case report suggests that risankizumab, an effective therapy for Crohn's disease, may also be effective in treating Crohn's disease–associated IgAN.

show abstract